Meet The Company Creating Novel Products For The Treatment Of ADHD
Sign up for this week’s All Access giveaway here!
Shane Schaffer, CEO of Cingulate, Inc. (NASDAQ: CING), was a guest on Benzinga’s All Access on August 22, 2022.
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.
Watch the full interview here:
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Benzinga All Access Cingulate TherapeuticsBiotech Penny Stocks Interview General
